NCT00515632View on ClinicalTrials.gov

Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

409

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

October 31, 2009

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Balaglitazone

One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.

Trial Locations (1)

Unknown

Multi-center, Copenhagen

All Listed Sponsors
lead

Rheoscience A/S

OTHER

NCT00515632 - Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy | Biotech Hunter | Biotech Hunter